//
New studies: Vi-DT vaccine is safe and immunogenic, with booster dosing potentially eliciting long-term immune responses - EIN News
Skip to main content
pediatrics associates of dallas :: Article Creator Pediatric Diagnostic Associates Will Continue Serving Families As A Practice Independent Of CHI Memorial Pediatric Diagnostic Associates, which was previously associated with CHI Memorial Hospital, announced Thursday it will again become an independent practice under newly formed Scenic City Pediatrics PLLC. Effective Feb. 1, the medical group will enter a new contract with BlueCross BlueShield of Tennessee, including Networks P and S, among other insurers, according to a news release. The change follows a June decision on BlueCross BlueShield of Tennessee's behalf to terminate its contract with Memorial relating to its Network S customers. Managing Partner Dr. Tony Friddell said in a phone interview Pediatric Diagnostic Associates has been under the CHI Memorial umbrella as a managed practice within the hospital system for 28 years. In some shape or form, Pediatric Diagnostic Associates...
Get link
Facebook
X
Pinterest
Email
Other Apps
New studies: Vi-DT vaccine is safe and immunogenic, with booster dosing potentially eliciting long-term immune responses - EIN News
Get link
Facebook
X
Pinterest
Email
Other Apps
-
We are confident that with these results, we are close to achieving our goal of developing a safe, effective, and affordable vaccine with long-lasting immunogenicity to protect against typhoid fever"
— Dr. Sushant Sahastrabuddhe, Associate Director General of IVI
SEOUL, REPUBLIC OF KOREA, January 28, 2022 /EINPresswire.com/ -- A new study shows that late booster dosing with Vi polysaccharide conjugated with diphtheria toxoid (Vi-DT), one of the typhoid conjugate vaccines (TCVs), at 27.5 months post-first dose is safe and elicits robust immune responses in children aged 6-23 months. The findings from this study newly published online in npj Vaccines support the use of TCV booster doses to confer long-term protection against typhoid fever in young children. This publication, co-authored by Drs. Birkneh Tilahun Tadesse and Maria Rosario Capeding, reports the results from the Phase II clinical trial of Vi-DT conducted by the International Vaccine Institute (IVI) in collaboration with the Research Institute for Tropical Medicine in Manila, the Philippines and SK bioscience in South Korea.
The average annual cases of typhoid fever are estimated to be 15 million worldwide, with infants and children especially exposed to the risk of mortality and morbidity from complications of typhoid fever. Over the past decade, significant progress in the development of TCVs has presented an opportunity to control and potentially eliminate typhoid in high burden settings, yet there is limited understanding of the long-term persistence of immune response and protection against typhoid fever following vaccination using single dose of the new-generation TCVs. This study is a critical step in the ongoing efforts to understand vaccine efficacy, effectiveness, and long-term immunogenicity enabled by a Vi-DT booster dose.
A pivotal Phase III study conducted by IVI in collaboration with SK bioscience involving four hospitals in Kathmandu, Dhulikhel, Dharan, and Nepalgunj in Nepal has shown that the Vi-DT test vaccine is safe, immunogenic, and non-inferior to the WHO prequalified Vi polysaccharide-tetanus toxoid (Vi-TT) Typbar TCV vaccine in individuals aged 6 months to 45 years. Dr. Tarun Saluja, Project Technical Lead and one of the lead-authors, says that this trial paves the way for licensure of Vi-DT and from there to wider access in the endemic countries. The manuscript is published online in The Lancet Infectious Diseases in December 2021.
"These two studies investigated critical data gaps and findings will be important for WHO prequalification of this vaccine. We are confident that with these results, we are close to achieving our goal of developing a safe, effective, and affordable vaccine with long-lasting immunogenicity to protect individuals, especially infants and children, against typhoid fever," said Dr. Sushant Sahastrabuddhe, Associate Director General at IVI and Director of the Typhoid Program.
Vi-DT was developed at IVI and its technology was transferred in 2013 to SK bioscience for manufacturing and commercialization. Following a Phase I safety trial with participants aged 2-45 years and a Phase II trial with infants under 2 years in the Philippines, large-scale Phase III studies with a single dose of Vi-DT started in the Philippines and Nepal in 2020. Vi-DT was shown to be safe in all trial participants and met its primary endpoints at the end of 2020. The vaccine will be submitted to the WHO for prequalification review after the Korean Ministry of Food and Drug Safety approves SK bioscience's Marketing Authorization request, responding to the need for sufficient and sustainable supply of TCVs to prevent and control typhoid fever globally.
About typhoid Typhoid fever is an invasive water-borne bacterial infection caused by Salmonella enterica serovar Typhi (S. Typhi) presenting with mild to severe symptoms and even resulting in death. Typhoid is most often contracted through ingestion of food or drink contaminated by bacteria shed by infected people. It is usually characterized by fever, headache, constipation, and malaise, though diagnosis can be difficult due to symptoms common to other febrile illnesses. Figures for burden of disease vary due to this difficulty, however the World Health Organization estimates that 128,000-161,000 people die every year from typhoid fever with 11-21 million annual cases.[1] Typhoid surveillance studies report that a quarter to more than half of all invasive cases are found in children under 5.[2]
[1] https://apps.who.int/iris/bitstream/handle/10665/272272/WER9313.pdf?ua=1 [2] J A Crump, E D Mintz Global trends in typhoid and paratyphoid Fever. ClinInfect Dis 2010;50(2):241–246.
###
About the International Vaccine Institute (IVI) The International Vaccine Institute (IVI) is a nonprofit inter-governmental organization established in 1997 at the initiative of the United Nations Development Programme (UNDP). IVI has 36 signatory countries and the World Health Organization (WHO) on its treaty, including Korea, Sweden, India, and Finland as state funders.
Our mandate is to make vaccines available and accessible for the world's most vulnerable people. We focus on infectious diseases of global health importance such as cholera, typhoid, shigella, salmonella, schistosomiasis, chikungunya, group A strep, Hepatitis A, HPV, TB, HIV, MERS, COVID-19, as well as antimicrobial resistance. For more information, please visit https://www.ivi.int
Vanessa Lee International Vaccine Institute +82 2-881-1510 vanessa.lee@ivi.int
advanced primary care of the ozarks :: Article Creator Integrating Rx With Advanced Primary Care Will Unlock Better Health America's healthcare industry has been squeezed tightly over the past few years with post-pandemic fallout, a declining economy and high consumer expectations. Retail pharmacies are no exception, and it's clear that the traditional pharmacy model is in crisis. With rising costs for medications and supplies and changing consumer retail habits, this doesn't bode well for the brick-and-mortar community pharmacy. Simply put: the traditional pharmacy model is unsustainable. We will soon see a rash of closing retail pharmacies and consumers scrambling to fill needed prescriptions affordably. You might be asking yourself why this should matter to you as HR and benefit professionals. I serve as chief human resources officer for a company that works with many large employers concerned about healthcare costs and the de...
podiatry billing company :: Article Creator The Best Medical Billing Services Of 2024 1. Get a full picture of the company's features. Claim scrubbing and follow-up are par for the course. You'll also commonly find that RCM companies include reporting, consultation, and EMR and PMS access with your services. Check for these features as you speak with company representatives. You should also determine whether the features that accompany your medical billing leave the company or your own team responsible for entering and coding charges. It's worth asking if your billing service candidates are following the most recent ICD-10 coding system updates. You should also get a sense of the billing company's experience with other practices in your specialty. Lastly, ask about the depth and extent of reporting and analytics solutions. "You'll want to ensure that your medical billing service has implemented & maintains timely bill...
women's preventive services :: Article Creator Women - Search News Team USA wins women's 4x400 for eighth consecutive Olympic gold medal The U.S. Women's have dominated the 4x400 relay, winning eight golds in a row in the event. When Team USA won it in Tokyo it gave the legendary Allyson Felix her 11th Olympic medal, making her the most decorated track and field athlete of all time.
Comments
Post a Comment